Form 4: Bicycle Therapeutics CAO Receives Equity Awards

Bicycle Therapeutics' Chief Accounting Officer, Travis Thompson, was granted 37,500 restricted share units and 75,000 stock options, alongside mandated 'sell to cover' transactions for tax obligations.

Summary

• Travis Thompson, Chief Accounting Officer of Bicycle Therapeutics PLC, was granted 37,500 Restricted Share Units (RSUs) on January 2, 2026.
• These RSUs represent a contingent right to receive one ordinary share each, with 25% vesting on January 2, 2027, and the remainder vesting in 12 equal quarterly installments thereafter.
• Thompson also received an award of 75,000 employee stock options on January 2, 2026, with an exercise price of $7.08.
• One-fourth of these options will vest on January 2, 2027, with the remaining shares vesting in 36 equal monthly installments thereafter, expiring on January 2, 2036.
• To cover statutory tax withholding obligations related to RSU vesting, Thompson sold 1,317 ordinary shares at a weighted average price of $6.80 on January 2, 2026.
• Additionally, 1,115 ordinary shares were sold at a weighted average price of $6.45 on January 5, 2026, for the same tax withholding purpose.
• These sales were mandated "sell to cover" transactions and do not represent discretionary sales by the reporting person.
• Following these transactions, Thompson beneficially owns 66,265 ordinary shares and 75,000 employee stock options.

Sentiment

Score: 7

Explanation: The filing indicates a positive move for executive retention and alignment through significant equity awards, which is generally favorable. The sales are non-discretionary for tax purposes, mitigating any negative sentiment from a reduction in direct ownership.

Positives

• Grant of 37,500 Restricted Share Units (RSUs) to the Chief Accounting Officer, aligning executive incentives with shareholder value.
• Grant of 75,000 employee stock options with an exercise price of $7.08, providing long-term incentive for the Chief Accounting Officer.
• The equity awards demonstrate continued commitment and retention of key management personnel.

Negatives

• The sale of 2,432 ordinary shares (1,317 and 1,115) by the Chief Accounting Officer, although mandated for tax purposes, reduces direct share ownership.

Future Outlook

The vesting schedules for the granted RSUs and stock options extend into future years, indicating a long-term incentive structure for the Chief Accounting Officer. The RSUs will vest quarterly after the initial 25% in 2027, and the options will vest monthly after the initial 25% in 2027, both over several years.

Industry Context

Equity awards like RSUs and stock options are standard practices in the biotechnology and pharmaceutical industries to attract, retain, and incentivize key executives, aligning their interests with long-term company performance and shareholder value creation. The "sell to cover" mechanism for tax withholding is also a common, non-discretionary practice for equity compensation.

Comparison to Industry Standards

• The grant of RSUs and stock options to a Chief Accounting Officer is a standard practice for executive compensation in publicly traded biotechnology companies like Bicycle Therapeutics PLC, comparable to compensation structures seen at companies such as Moderna (MRNA) or BioNTech (BNTX) for their executive teams.
• The vesting schedules, with an initial cliff vesting followed by periodic installments, are typical for long-term incentive plans designed to retain executives over several years.
• The "sell to cover" transaction for tax obligations is a widely accepted and common method for satisfying statutory tax withholdings upon the vesting or exercise of equity awards across all industries, including biotech.

Stakeholder Impact

• Shareholders: The equity awards align the Chief Accounting Officer's interests with long-term shareholder value. The "sell to cover" transactions have a minor dilutive effect but are standard for tax purposes.
• Employees: Reflects standard executive compensation practices, potentially signaling stability in leadership.

Next Steps

• One-fourth of the 37,500 RSUs will vest on January 2, 2027, with the remaining RSUs vesting in 12 equal quarterly installments thereafter.
• One-fourth of the 75,000 employee stock options will vest on January 2, 2027, with the remaining options vesting in 36 equal monthly installments thereafter.

Key Dates

Recommendation

This Form 4 primarily details routine executive compensation in the form of equity grants and mandated tax-related share sales. It does not provide new information about the company's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. The awards are a standard practice for executive retention and alignment, and the sales are non-discretionary. Therefore, a "hold" recommendation is appropriate as this filing does not present new fundamental data to alter an existing investment thesis.

Keywords

Bicycle Therapeutics, BCYC, Form 4, Insider Transaction, Restricted Share Units, RSU, Stock Options, Equity Award, Chief Accounting Officer, Travis Thompson, Sell to Cover, Executive Compensation, Share Ownership